"Biotech Battle: Natera's Legal Victory and Financial Fallout"

Natera stock surged after a jury ruled it must pay competitor Ravgen $57 million in a patent lawsuit, significantly less than the $410 million originally requested. Analysts believe this won't affect Natera's plans to achieve cash-flow break-even in 2024 and the company intends to appeal the decision. The patents in question have expired, and Natera's robust patent portfolio is seen as an underappreciated asset. Despite the legal setback, Natera's stock broke out of a cup-with-handle base last month and has a strong 12-month performance, placing it in the top 6% of all stocks.